Filter Results:
(446)
Show Results For
- All HBS Web
(631)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Show Results For
- All HBS Web
(631)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Sort by
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Biotechnology Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
- September 2023 (Revised April 2024)
- Case
Atomwise: Strategic Opportunities in AI for Pharma
By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Biotechnology Industry; Biotechnology Industry
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)
- January 2014
- Supplement
Amgen Inc.: Pursuing Innovation and Imitation? (B)
By: Ian Mackenzie
The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details
Mackenzie, Ian. "Amgen Inc.: Pursuing Innovation and Imitation? (B)." Harvard Business School Supplement 714-426, January 2014.
- June 2012
- Case
GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships
By: Arthur A. Daemmrich and Ian McKown Cornell
Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric... View Details
Keywords: Public-Private Partnerships; Business and Government Relations; Foreign Direct Investment; Health Care and Treatment; Globalized Firms and Management; Biotechnology Industry; Biotechnology Industry; Brazil
Daemmrich, Arthur A., and Ian McKown Cornell. "GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships." Harvard Business School Case 712-049, June 2012.
- April 2011
- Supplement
Roche's Acquisition of Genentech (CW)
By: Bo Becker
Spreadsheet for case 210040. View Details
- March 2011 (Revised June 2012)
- Case
Office of Technology Transfer - Shanghai Institutes for Biological Sciences
By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland
Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing... View Details
Keywords: Multinational Firms and Management; Patents; Knowledge Management; Law Enforcement; Business and Government Relations; Research and Development; Biotechnology Industry; Biotechnology Industry; China
Shih, Willy, Sen Chai, Kamen Bliznashki, and Courtney Hyland. "Office of Technology Transfer - Shanghai Institutes for Biological Sciences." Harvard Business School Case 611-057, March 2011. (Revised June 2012.)
- 24 Jun 2008
- Conference Presentation
The effect of heterogeneous institutional actors on entrepreneurial activity and resource attainment in the U.S. biodiesel industry
By: Shon R. Hiatt
- 2010
- Working Paper
Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe
By: Christopher C. Liu and Toby E. Stuart
In innovative industries, private-sector companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries.... View Details
Keywords: For-Profit Firms; Higher Education; Information Publishing; Innovation and Invention; Science-Based Business; Social and Collaborative Networks; Boundaries; Biotechnology Industry; Biotechnology Industry
Liu, Christopher C., and Toby E. Stuart. "Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe." Harvard Business School Working Paper, No. 11-012, August 2010.
- November 2007
- Class Lecture
The Baby Business (FSS)
By: Debora L. Spar
In vitro fertilization and genetic screening are possible with the advent of biotechnology. International adoptions, surrogacy, and other approaches to family planning are on the rise. But few rules govern these measures, medical costs can be prohibitive, and... View Details
Keywords: Governing Rules, Regulations, and Reforms; Policy; Demand and Consumers; Business and Government Relations; Business and Stakeholder Relations; Genetics; Societal Protocols; Commercialization; Biotechnology Industry; Biotechnology Industry
Spar, Debora L. "The Baby Business (FSS)." Harvard Business School Class Lecture 708-701, November 2007.
- November 2007
- Case
Antegren: A Beacon of Hope
By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details
Keywords: Demand and Consumers; Leadership; Ethics; Corporate Social Responsibility and Impact; Decision Choices and Conditions; Crisis Management; Health Testing and Trials; Biotechnology Industry; Biotechnology Industry
Margolis, Joshua D., Thomas J. DeLong, and Terence Heymann. "Antegren: A Beacon of Hope." Harvard Business School Case 408-025, November 2007.
- June 2004 (Revised May 2005)
- Case
Judah Folkman and the War on Cancer
Judah Folkman, professor in the Division of Vascular Biology at Children's Hospital in Boston, is considering how best to advance the research in his lab in an era where biomedical research has gotten more interdisciplinary and collaborative. Specifically, Folkman has... View Details
Keywords: Conflict of Interests; Leadership; Research; Personal Development and Career; Health Care and Treatment; Collaborative Innovation and Invention; Biotechnology Industry; Biotechnology Industry; Boston
West, Jonathan, Ambuj Sagar, and Mona Ashiya. "Judah Folkman and the War on Cancer." Harvard Business School Case 604-091, June 2004. (Revised May 2005.)
- September 1995
- Case
Ares-Serono
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details
Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Biotechnology Industry; Biotechnology Industry; Switzerland; Europe
Yoshino, Michael Y., Jean-Pierre Jeannet, and Carin-Isabel Knoop. "Ares-Serono." Harvard Business School Case 396-035, September 1995.
- 15 Feb 2000
- Research & Ideas
The Right Connections
of IPO Team Ties on Investment Bank Affiliation and IPO Success," which examines how individuals' affiliations can affect the formation of alliances at the firm level. To that end, the researchers pinpointed the biotechnology... View Details
Keywords: by Judith A. Ross
- 26 Jun 2000
- Research & Ideas
Presentation Round-Up
recently joined with the private company Celera Genomics to announce the cracking of the human genetic code.) Increasing interest in such research has led to complex legal tangles. Patent attorney Brenda Herschbach Jarrell of Choate, Hall & Stewart, who specializes... View Details
- 22 Sep 2009
- First Look
First Look: September 22
biotechnology company, launches a program to develop therapies for neglected diseases (e.g., malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets... View Details
Keywords: Martha Lagace
- September 2012 (Revised September 2012)
- Course Overview Note
Building Life Science Businesses Fall 2012: Course Outline and Syllabus
This Course Outline and Syllabus gives an overview of the Fall 2012 class Building Life Science Businesses View Details
- July 2014 (Revised January 2017)
- Course Overview Note
Building Life Science Businesses Spring Term 2017: Course Outline and Syllabus
This Course Outline and Syllabus gives an overview of the Spring 2016 class Building Life Science Businesses.7 View Details
Keywords: Healthcare Ventures; Entrepreneurial Management; Entrepreneurship; Entrepreneurs; Health Care and Treatment; Health Testing and Trials; Medical Specialties; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Asia; North America; Europe
Hamermesh, Richard G. "Building Life Science Businesses Spring Term 2017: Course Outline and Syllabus." Harvard Business School Course Overview Note 815-003, July 2014. (Revised January 2017.)
- 03 Aug 2010
- First Look
First Look: August 3
Baldwin, Bo Becker, and Vincent DessainHarvard Business School Case 210-040 Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly owned shares of Roche's biotechnology subsidiary,... View Details
Keywords: Martha Lagace
- 22 Sep 2020
- Research & Ideas
Recessions Push Some Entrepreneurs to Launch Too Soon
an associate professor at University of Lausanne, studied 3,025 US founders from 2005 to 2012 and their 1,747 startups in the biotechnology and medical device sectors during previous economic downturns. Their research was conducted before... View Details
Keywords: by Sean Silverthorne
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
challenges, not on the hard work of winning hearts and minds, Shapiro ultimately lost his company. He was forced to sell Monsanto to Pharmacia-Upjohn, which bought it for its pharmaceutical division, valuing the agricultural biotechnology... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman